

Mohammad Tabrizi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12022356/publications.pdf>

Version: 2024-02-01

14
papers

780
citations

1040056

9
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

1133
citing authors

#	ARTICLE	IF	CITATIONS
1	Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease. AAPS Journal, 2010, 12, 33-43.	4.4	254
2	Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD. Chest, 2004, 126, 926-934.	0.8	242
3	A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models. Molecular Cancer Therapeutics, 2010, 9, 145-156.	4.1	133
4	Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies. AAPS Journal, 2010, 12, 592-601.	4.4	31
5	Application of Analytical Detection Concepts to Immunogenicity Testing. Analytical Chemistry, 2007, 79, 8176-8184.	6.5	22
6	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs, 2010, 28, 561-574.	2.6	22
7	Surrogate approaches in development of monoclonal antibodies. Drug Discovery Today, 2009, 14, 1159-1165.	6.4	20
8	Exposure-Response Relationships for Therapeutic Biologic Products. , 2006, , 295-327.		16
9	Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases. Inflammation and Allergy: Drug Targets, 2010, 9, 229-237.	1.8	15
10	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66.	4.4	10
11	Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation. AAPS Journal, 2019, 21, 39.	4.4	10
12	Cytokine Therapeutics in Cancer Immunotherapy: Design and Development. Current Pharmacology Reports, 2019, 5, 377-390.	3.0	4
13	Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics. , 2012, , 141-151.		1
14	Strategies for Development of Next Generation Antibody-Based Therapeutics. , 2012, , 375-390.		0